Physician profile
Deepika Wali
NPI 1144205295
$562.88
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $109 · 2021: $18.14 · 2022: $25.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $138.43 | 2019-2020 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $84.36 | 2019 | |
| Clovis Oncology, INC. | $34.40 | 2019 | |
| Pfizer INC. | $26.87 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $25.92 | 2019 | |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Genentech USA, INC. | $23.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.22 | 2019 | |
| Janssen Biotech, INC. | $19.47 | 2019 | |
| Kite Pharma, INC. | $18.14 | 2021 | |
| Tesaro, INC. | $16.14 | 2019 | |
| Genzyme Corporation | $14.45 | 2020 | |
| Eisai INC. | $12.64 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Wali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.